Sodium Phosphate, Dibasic and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Sodium Phosphate, Dibasic
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect your heart's rhythm. Buprenorphine is a strong pain and addiction medicine, and dibasic sodium phosphate is a mineral product often used to help empty the bowels or as a supplement. Both can slightly stretch out a part of your heartbeat called the QT interval. When you take them together, that effect could add up and, in rare cases, lead to an irregular heartbeat.
This is a theoretical concern, meaning it hasn't been proven to happen often, but it's worth taking seriously. The good news is your care team can manage this easily by checking your heart and your mineral levels. Please don't stop either medicine on your own, just talk with your pharmacist or doctor.
Effect: Additive QT-interval prolongation with combined buprenorphine and dibasic sodium phosphate.
Mechanism: Pharmacodynamic (additive) QT prolongation, not a metabolic/PK interaction. Neither agent is a prodrug; direction is additive effect on cardiac repolarization.
Evidence: Theoretical; combined risk not quantified. Onset unspecified.
- Higher concern with hypokalemia, hypomagnesemia, bradycardia, CHF, recent AF conversion, digitalis therapy, or baseline/congenital long-QT.
- Note phosphate products can shift electrolytes, potentially worsening QT risk.
Management: Avoid concomitant use where feasible; otherwise correct/monitor electrolytes (K+, Mg2+), consider ECG monitoring, and individualize based on cumulative QT risk factors.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
The simultaneous administration of buprenorphine alongside agents capable of prolonging the QT interval should be avoided342. It remains unknown what risk arises from pairing buprenorphine with other QT prolongation agents. When prescribing buprenorphine to patients who carry risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, take these observations into account during clinical decision-making1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because both can lengthen the QT interval, here is how a care team typically handles this:
- They may check whether you have other QT risk factors (low potassium or magnesium, slow heart rate, heart failure, or a known long-QT condition).
- They may order an ECG (heart tracing) and blood tests to check your mineral levels.
- In some cases they may choose an alternative product or adjust timing, tailored to you.
What to do: Tell your pharmacist or prescriber you take both, and report any fainting, dizziness, or a pounding or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Sodium Phosphate, Dibasic and Buprenorphine together?
Buprenorphine and dibasic sodium phosphate can each stretch the heart's QT interval, so combining them may add up; this is a theoretical concern that your care team can manage by checking your electrolytes and heart rhythm. Don't stop either drug on your own, and report fainting or an irregular heartbeat. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sodium Phosphate, Dibasic and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Sodium Phosphate, Dibasic and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because both can lengthen the QT interval, here is how a care team typically handles this: They may check whether you have other QT risk factors (low potassium or magnesium, slow heart rate, heart failure, or a known long-QT condition). They may order an ECG (heart tracing) and blood tests to check your mineral lev… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Sodium Phosphate, Dibasic or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Sodium Phosphate, Dibasic
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist